Fig. 1 · Structure

Documents & Downloads

Defactinib (PF-04554878)

Cat. No. A21958 CAS 1073154-85-4

FAK inhibitor

Defactinib (VS-6063; PF-04554878) is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities.

In Stock

Publications for Defactinib

1 publication citing this product

  1. Shalana O'Brien, .et al. , Oncotarget., 2014, Sep; 5(17): 7945-7959 PMID: 25277206

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Defactinib (VS-6063/PF-04554878) suppressed cellular FAK Tyr397 phosphorylation in HeyA8 and HeyA8-MDR ovarian cancer cells. At 1 µmol/L, inhibition was evident early and phosphorylation gradually returned by 48 h. [1]

In RAW264.7 macrophages, 1 µM defactinib reduced IRF5-associated TNF reporter activity in wild-type and IRF5-complemented cells, but produced no significant additional inhibition in PYK2-deficient cells. This supports PYK2-dependent activity in that cellular assay. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
A375P GI50 5.94 μM Antiproliferative activity against human A375P cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay [PMID: 34324343]
A549 IC50 4.09 μM Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 34091209]
BXPC-3 IC50 3.25 μM Antiproliferative activity against human BxPC-3 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 34091209]
HCT-116 IC50 2.65 μM Antiproliferative activity against human HCT116 cells overexpressing FAK assessed as reduction in cell viability after 72 hrs by MTS assay [PMID: 31129452]
HCT-116 GI50 9.13 μM Antiproliferative activity against human HCT-116 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay [PMID: 34324343]
HCT-15 IC50 4.36 μM Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 34091209]
HEK293 IC50 4.07 μM Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 34091209]
HepG2 IC50 3.69 μM Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 34091209]
HUVEC IC50 3.24 μM Antiproliferative activity against human HUVEC cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 34091209]
L02 IC50 4.66 μM Antiproliferative activity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 34091209]
MCF-10A IC50 18.42 μM Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 72 hrs by MTS assay [PMID: 31129452]
MCF7 IC50 5.81 μM Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 34091209]
MCF7 IC50 8.97 μM Antiproliferative activity against human MCF7 cells overexpressing FAK assessed as reduction in cell viability after 72 hrs by MTS assay [PMID: 31129452]
MDA-MB-231 GI50 11.45 μM Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay [PMID: 34324343]
MDA-MB-231 IC50 3.75 μM Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 34091209]
PANC-1 IC50 3.48 μM Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 34091209]
PC-3 IC50 > 20 μM Antiproliferative activity against human PC3 cells overexpressing FAK assessed as reduction in cell viability after 72 hrs by MTS assay [PMID: 31129452]
U-87MG ATCC IC50 10.21 μM Antiproliferative activity against human U87MG cells overexpressing FAK assessed as reduction in cell viability after 72 hrs by MTS assay [PMID: 31129452]

18 records · Scroll to view more

Defactinib (PF-04554878) Research Summary

This section summarizes 3 in vitro studies of Defactinib (PF-04554878) from 3 published references. In vitro models include HeyA8 and HeyA8-MDR ovarian cancer cells; TT, TPC1, K1 and BCPAP thyroid cancer cell lines.

Defactinib (PF-04554878) In Vitro Studies

After 24 h treatment, reported PF-04554878 MTS viability IC50 values were 1.98 µM in TT, 23.04 µM in TPC1, 10.34 µM in K1 and >50 µM in BCPAP cells. The variation limits extrapolation of cellular sensitivity across thyroid cancer models. [3]

Time-dependent suppression and recovery of FAK phosphorylation

Cell-based study · HeyA8 and HeyA8-MDR ovarian cancer cells [1]

VS-6063 reduced pFAK Tyr397 during early exposure, with recovery at later time points. This is a cellular phosphorylation endpoint, not an enzyme IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
FAK Tyr397 phosphorylation relative to total FAKqualitative time course Early inhibition; gradual return by 48 h[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 µmol/L
Exposure duration
1, 3, 24 and 48 h
Method
Western blot; pFAK Tyr397 intensity relative to total FAK; untreated comparison
Reported limits
Vehicle composition was not established from the retrieved main text; linked supplementary DOCX was not retrieved.
Methods and source locations

Compound reported in the paper: Defactinib; Compound label in the paper: VS-6063 (formerly PF-04554878)

Compound-level research findings; no salt conversion or current Adooq lot validation.

Figure 1B and caption; Results: Effect of FAK Inhibition on Sensitivity to PTX; Methods: Western Blot Analysis

FAK Tyr397 phosphorylation relative to total FAK: Triplicate experiments; mean ± standard deviation; caption uses *P < .01 versus untreated. — Figure 1B and caption; Results: Effect of FAK Inhibition on Sensitivity to PTX; Methods: Western Blot Analysis

PYK2-dependent inhibition of IRF5-driven TNF reporter activity

Cell-based study · Wild-type, IRF5-knockout and PYK2-knockout RAW264.7 macrophages, with empty-vector or IRF5-expression controls [2]

Defactinib reduced stimulated TNF reporter activity in wild-type cells and IRF5-deficient cells complemented with IRF5, but not in PYK2-deficient cells. Genetic controls support pathway dependence within this reporter system.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IRF5-associated TNF-luciferase activity in wild-type and knockout cellsqualitative reporter response Inhibition with functional PYK2; no significant additional inhibition in PYK2-knockout cells[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 µM
Exposure duration
1 h pretreatment followed by 6 h stimulation
Method
TNF-luciferase reporter, with unstimulated controls and LPS stimulation (1 µg/mL)
Vehicle
DMSO control
Reported limits
Salt form and supplier were not established in the read source. No biochemical binding or enzyme potency is inferred.
Methods and source locations

Compound reported in the paper: Defactinib; Compound label in the paper: Defactinib (VS-6063; PF-04554878)

Compound-level research findings; no salt conversion or current Adooq lot validation.

Figure 4a and caption; Results: A PYK2 inhibitor Defactinib interferes with IRF5 activation; Supplementary Figure 5a (PDF page 6)

IRF5-associated TNF-luciferase activity in wild-type and knockout cells: Figure 4a: mean ± SEM, n = 3 independent experiments; two-way ANOVA with Tukey correction. Supplementary Figure 5a checks viability at the selected exposure. — Figure 4a and caption; Results: A PYK2 inhibitor Defactinib interferes with IRF5 activation; Supplementary Figure 5a (PDF page 6)

Model-dependent thyroid cancer cell viability response

Cell-based study · TT, TPC1, K1 and BCPAP thyroid cancer cell lines [3]

Reported PF-04554878 MTS viability responses differed across cell lines. BCPAP did not reach a reported IC50 within 50 µM. These are cellular viability values, not purified FAK inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TT cellular viabilityIC50 1.98 µM[3]
TPC1 cellular viabilityIC50 23.04 µM[3]
K1 cellular viabilityIC50 10.34 µM[3]
BCPAP cellular viabilityIC50 >50 µM[3]

Literature-Reported Treatment Conditions

Treatment concentration
0, 1, 5, 10 and 50 µM (Figure 3C)
Exposure duration
24 h
Method
MTS viability at 490 nm; zero-dose comparison
Vehicle
DMSO stock; final assay percentage not stated in read methods
Reported limits
A matched DMSO-only comparison is not explicitly documented in the read assay description; salt/lot specification is not provided.
Methods and source locations

Compound reported in the paper: Defactinib; Compound label in the paper: PF-04554878

Compound-level research findings; no salt conversion or current Adooq lot validation.

Figure 3B right-hand IC50 table and Figure 3C; Results: Y15 inhibited cell viability; Methods: Small molecule inhibitors, Viability, Statistical analysis

TT cellular viability: MTS at 24 h; authors’ fitted values confirmed in viewed Figure 3B table. Each sample analyzed in triplicate; independent experiment count not specified here. — Figure 3B right-hand IC50 table and Figure 3C; Results: Y15 inhibited cell viability; Methods: Small molecule inhibitors, Viability, Statistical analysis

TPC1 cellular viability: MTS at 24 h; authors’ fitted values confirmed in viewed Figure 3B table. Each sample analyzed in triplicate; independent experiment count not specified here. — Figure 3B right-hand IC50 table and Figure 3C; Results: Y15 inhibited cell viability; Methods: Small molecule inhibitors, Viability, Statistical analysis

K1 cellular viability: MTS at 24 h; authors’ fitted values confirmed in viewed Figure 3B table. Each sample analyzed in triplicate; independent experiment count not specified here. — Figure 3B right-hand IC50 table and Figure 3C; Results: Y15 inhibited cell viability; Methods: Small molecule inhibitors, Viability, Statistical analysis

BCPAP cellular viability: MTS at 24 h; authors’ fitted values confirmed in viewed Figure 3B table. Each sample analyzed in triplicate; independent experiment count not specified here. — Figure 3B right-hand IC50 table and Figure 3C; Results: Y15 inhibited cell viability; Methods: Small molecule inhibitors, Viability, Statistical analysis

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1073154-85-4
Alternate CAS 1345713-71-4
Applications FAK inhibitor
Formula C20H21F3N8O3S
Molecular Weight 510.49
Synonyms VS-6063; PF-04554878
SMILES
O=C(NC)C1=CC=C(NC2=NC=C(C(F)(F)F)C(NCC3=NC=CN=C3N(C)S(=O)(C)=O)=N2)C=C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 5 mg/mL (9.79 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
5% DMSO+50% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Defactinib (PF-04554878) Research References

  1. [1] Kang Y, Hu W, Ivan C, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. Journal of the National Cancer Institute (2013). PMID: 24062525 DOI: 10.1093/jnci/djt210 Source material
  2. [2] Ryzhakov G, Almuttaqi H, Corbin AL, et al. Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation. Nature communications (2021). PMID: 34795257 DOI: 10.1038/s41467-021-27038-5 Source material
  3. [3] O'Brien S, Golubovskaya VM, Conroy J, et al. FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics. Oncotarget (2014). PMID: 25277206 DOI: 10.18632/oncotarget.2381 Source material

Publications

1 publication citing this product

  1. Shalana O'Brien, .et al. , Oncotarget., 2014, Sep; 5(17): 7945-7959 PMID: 25277206

Added to your cart

View Cart Checkout
Loading...